Pfizer and BioNTech To Initiate COVID-19 Vaccine Clinical Trials In April
The two companies announced more details about their COVID-19 vaccine development plan, including a $185m upfront payment and $113m equity investment from Pfizer.
You may also be interested in...
Pfizer said it is dosing patients now with an mRNA-based vaccine and expects human data in May/June, with a goal to have a vaccine available for emergency use possibly by October.
The two RNAi firms cross-license IP from their PH programs, while also partnering on a rare liver disease candidate. GSK invests $250m in Vir and will help to advance its antibody candidates for COVID-19.
Plus: Lilly unveils Olumiant COVID-19 study, Samsung and Vir to collaborate on antibody, Korean industry asks for government assistance.